Overview

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Status:
Completed

Trial end date:
2016-01-27

Target enrollment:

Participant gender:

Summary

This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.

Phase:

Phase 3

Details

Lead Sponsor:

GW Pharmaceuticals Ltd.

Collaborator:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Treatments:

Nabiximols